Key result
Impaired endothelial nitric oxide bioavailability is linked to accelerated vascular aging, hypertension, and atherogenesis.
Why the study?
Impaired endothelial nitric oxide bioavailability is associated with aging, hypertension, and atherogenesis, but its role as a modifiable vascular risk factor in older adults is unclear.
Does pharmacotherapy aimed at improving endothelial NO bioavailability modify age-related vascular disease in older adults?
Population
Older adults and models of healthy aging, atherosclerosis, and hypertension
Comparison
Pharmacotherapy aimed at improving endothelial NO bioavailability versus no such intervention
Design
Review
Authors
Loading...
May support endothelial NO as a therapeutic target in older adults; leaves open whether pharmacotherapy modifies vascular aging.
Does pharmacotherapy aimed at improving endothelial NO bioavailability modify age-related vascular disease in older adults?
Improving endothelial NO bioavailability through pharmacotherapy such as ACE inhibitors and statins may help modify age-related vascular risk.
Donnelly et al. (2008) conducted a review in Aging, hypertension, and atherogenesis. Impaired endothelial nitric oxide bioavailability was evaluated. Impaired endothelial nitric oxide bioavailability is associated with accelerated vascular aging, hypertension, and atherogenesis, suggesting it may be a modifiable vascular risk factor in older adults.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: